Background Optimum management of clinically localised prostate cancer presents unique
challenges because of the highly variable and often indolent natural history of the disease …

Glioblastoma multiforme (GBM) has a poor prognosis despite maximal multimodal therapy.
Biomarkers of relevance to prognosis which may also identify treatment targets are needed …

Glioblastoma (GBM) is both the most common and the most lethal primary brain tumor. It is
thought that GBM stem cells (GSCs) are critically important in resistance to therapy …

Background Glioblastoma is a complex multifactorial disorder that has swift and devastating
consequences. Few genes have been consistently identified as prognostic biomarkers of …

Gene co-expression network analysis is an effective method for predicting gene functions
and disease biomarkers. However, few studies have systematically identified co-expressed …

Survival in the majority of high-grade astrocytoma (HGA) patients is very poor, with only a
rare population of long-term survivors. A better understanding of the biological factors …

To determine a molecular basis for prognostic differences in glioblastoma multiforme (GBM),
we employed a combinatorial network analysis framework to exhaustively search for …

Current cancer management aims to integrate molecular signatures into the design of
personalized therapies. Recent advances in “omics” done on tumor specimens have led to …

Background Recent research on glioblastoma (GBM) has focused on deducing gene
signatures predicting prognosis. The present study evaluated the mRNA expression of …

Although patients with Glioblastoma multiforme (GBM) have grave prognosis, significant
variability in patient outcome is observed. The objective of this study is to identify a …